Cue Biopharma (CUE) Insider Trading & Ownership $1.01 -0.03 (-2.88%) (As of 01:48 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Cue Biopharma (NASDAQ:CUE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.26%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$30,900.00Number OfInsiders Selling(Last 12 Months)0 Get CUE Insider Trade Alerts Want to know when executives and insiders are buying or selling Cue Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CUE Insider Buying and Selling by Quarter Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Cue Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/16/2024Daniel R PasseriCEOBuy30,000$1.03$30,900.00 (Data available from 1/1/2013 forward) CUE Insider Trading Activity - Frequently Asked Questions Who is on Cue Biopharma's Insider Roster? The list of insiders at Cue Biopharma includes Aaron G.L. Fletcher, Anish Suri, Daniel R Passeri, and Peter A Kiener. Learn more on insiders at CUE. What percentage of Cue Biopharma stock is owned by insiders? 12.26% of Cue Biopharma stock is owned by insiders. Learn more on CUE's insider holdings. Which Cue Biopharma insiders have been buying company stock? The following insiders have purchased CUE shares in the last 24 months: Anish Suri ($11,040.00), and Daniel R Passeri ($39,480.00). How much insider buying is happening at Cue Biopharma? Insiders have purchased a total of 37,000 CUE shares in the last 24 months for a total of $50,520.00 bought. Which Cue Biopharma insiders have been selling company stock? The following insider sold CUE shares in the last 24 months: Peter A Kiener ($30,586.00). How much insider selling is happening at Cue Biopharma? Insiders have sold a total of 9,325 Cue Biopharma shares in the last 24 months for a total of $30,586.00 sold. Cue Biopharma Key ExecutivesMr. Daniel R. Passeri J.D. (Age 63)M.Sc., CEO & Director Compensation: $607.98k1 recent tradesDr. Anish Suri Ph.D. (Age 50)President & Chief Scientific Officer Compensation: $447.34kMs. Kerri-Ann Millar (Age 54)Chief Financial Officer Compensation: $447.34kDr. Ronald D. Seidel III (Age 48)Ph.D., Co-Founder Compensation: $316.63kMr. Colin G. Sandercock J.D. (Age 67)MSE, Senior VP, General Counsel & Secretary Compensation: $381.42kDr. Matteo Levisetti M.D. (Age 55)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Rezolute Insider Selling Fulcrum Therapeutics Insider Selling UroGen Pharma Insider Selling Heron Therapeutics Insider Selling Zentalis Pharmaceuticals Insider Selling DiaMedica Therapeutics Insider Selling Neoleukin Therapeutics Insider Selling Inhibrx Insider Selling Lexeo Therapeutics Insider Selling Cardiff Oncology Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:CUE) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CUE Stock Alerts